Cabotegravir is a second-generation integrase strand transfer inhibitor used as long-acting injectable HIV pre-exposure prophylaxis and in combination with rilpivirine for HIV-1 maintenance therapy, enabling monthly or bi-monthly dosing. Simson Pharma's Cabotegravir reference standard and impurities support analytical development for this long-acting antiretroviral.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cabotegravir Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.